Tag: Truvada

Should Truvada for HIV PrEP be covered under public drug plans? Participate in CTAC’s Patient Group Input Consultation on PrEP and share your experience and perspectives. Webinars: Truvada (TDF/FTC) to reduce the risk of HIV Infection in Adults (PrEP) Register for March 14, 2016, 1-2pm EDT Register for March 15, 2016,  8:30-9:30pm EDT On February… Read more »

In a press release issued on February 29, 2016, Gilead Sciences Inc announced Health Canada has approved Truvada® for use as pre-exposure prophylaxis, commonly known as PrEP, to reduce the risk of HIV infection in Canada. While news of Health Canada’s approval was positively received, access to the treatment is still a concern due to… Read more »

ACT – One Step Closer to Accessing PrEP in Canada

HIV prevention in Canada took a significant step forward today when pharmaceutical company Gilead Sciences Canada announced it is seeking approval for the use of Truvada as Pre Exposure Prophylaxis in Canada. The onus now sits with Health Canada and policy makers to ensure universal access and coverage of PrEP. Truvada used as PrEP is… Read more »

Open letter from HIM to Gilead Sciences re: PrEP

Health Iinitiative for Men (HIM) has written an Open Letter to Gilead Sciences, asking them to apply for Health Canada approval for use of Truvada in HIV pre-exposure prophylaxis. PrEP, or pre-exposure prophylaxis, is a new tool in HIV prevention. Someone who is HIV negative can take anti-HIV medications on a daily basis to reduce… Read more »